ArticleJournal of public health research2025
Mortality trends from respiratory disease in Kazakhstan: A 2011-2021 analysis.
Article in Journal of public health research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory diseases rank second in global morbidity and mortality. By 2020, mortality from these conditions surged by 39.8% due to increased incidence and COVID-19-related deaths. Objectives: This study aimed to identify preventable mortality and total mortality from respiratory diseases in Kazakhstan from 2011 to 2021. Design and methods: Data from the National Statistics Agency of the Republic of Kazakhstan were analyzed. Preventable mortality rates were calculated across 5-year age groups (i.e. 0, 1-4, 5-9, . . ., 74+) and by gender using respiratory disease mortality data from 2011 to 2021. In addition, 95% confidence intervals (95% CI) for the age group of 0-74 years and gender factors were calculated to ensure statistical reliability. Results: Preventable mortality levels have more than doubled by 2021, reaching 156.19 per 100,000 population, with a significant increase in 2020. Preventable mortality among men was consistently three or more times higher than among women. The average annual percentage change increased by 7.5% (95% CI: 3.1; 12.2), from 2011 to 2021, where the rate was higher among women 9.2% (95% CI: 4.8; 13.9), compared to men (6.6% [95% CI: 0.9; 12.7]). Our findings strongly indicate that mortality rates will continue to rise by 2026, underscoring the urgent need for the scientific community and governments to collaborate in preventing further escalations of respiratory diseases. Conclusions: The study seeks to project the future prognosis of respiratory disease-related mortality and to highlight the need for targeted health strategies to reduce avoidable deaths through targeted health strategies with cooperative measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.